Compare DH & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DH | ONCY |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 94.0M |
| IPO Year | 2021 | 2002 |
| Metric | DH | ONCY |
|---|---|---|
| Price | $1.06 | $1.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $3.08 | ★ $7.33 |
| AVG Volume (30 Days) | 248.8K | ★ 932.2K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $241,521,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.30 | $2,505.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.92 | $0.33 |
| 52 Week High | $4.70 | $1.51 |
| Indicator | DH | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 44.24 | 60.49 |
| Support Level | $0.97 | $1.10 |
| Resistance Level | $1.24 | $1.34 |
| Average True Range (ATR) | 0.09 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 43.75 | 95.32 |
Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.